Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERAS NASDAQ:OCUL NASDAQ:SDGR NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$1.49+3.5%$1.39$1.01▼$3.45$407.93M1.051.59 million shs915,350 shsOCULOcular Therapeutix$11.38+1.2%$8.72$5.79▼$11.78$1.79B1.431.44 million shs2.68 million shsSDGRSchrodinger$21.65+1.9%$21.99$16.60▼$28.47$1.56B1.58925,182 shs1.25 million shsSPRYARS Pharmaceuticals$18.35+2.7%$15.52$8.91▼$18.90$1.76B0.91.36 million shs1.81 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca+2.13%-6.49%+2.49%+24.14%-55.42%OCULOcular Therapeutix+1.44%+4.55%+28.57%+53.90%+33.93%SDGRSchrodinger+4.32%-1.98%+0.24%-17.48%-11.53%SPRYARS Pharmaceuticals+1.77%-0.17%+17.88%+20.09%+57.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERASErasca2.9668 of 5 stars3.52.00.00.02.22.51.3OCULOcular Therapeutix3.9272 of 5 stars3.52.00.04.12.22.50.0SDGRSchrodinger1.8106 of 5 stars3.41.00.00.01.81.70.6SPRYARS Pharmaceuticals2.8661 of 5 stars3.61.00.00.02.24.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 3.00Buy$4.57206.81% UpsideOCULOcular Therapeutix 3.00Buy$17.3352.31% UpsideSDGRSchrodinger 2.75Moderate Buy$32.7551.27% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.0068.94% UpsideCurrent Analyst Ratings BreakdownLatest ERAS, SPRY, SDGR, and OCUL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025SDGRSchrodingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $30.007/3/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$28.005/29/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/6/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$1.50 per shareN/AOCULOcular Therapeutix$63.72M28.45N/AN/A$2.01 per share5.66SDGRSchrodinger$207.54M7.65N/AN/A$5.78 per share3.75SPRYARS Pharmaceuticals$89.15M20.21$0.01 per share2,110.22$2.64 per share6.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$161.65M-$0.62N/AN/AN/AN/A-36.56%-31.08%8/11/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.15N/AN/AN/A-323.09%-59.92%-41.98%8/6/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.16N/AN/AN/A-16.11%-6.94%-5.60%8/5/2025 (Estimated)Latest ERAS, SPRY, SDGR, and OCUL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ERASErasca-$0.12N/AN/AN/AN/AN/A8/6/2025Q2 2025OCULOcular Therapeutix-$0.35N/AN/AN/A$13.12 millionN/A8/5/2025Q2 2025SPRYARS Pharmaceuticals-$0.42N/AN/AN/A$12.92 millionN/A7/30/2025Q2 2025SDGRSchrodinger-$0.83N/AN/AN/A$52.03 millionN/A5/14/2025Q1 2025SPRYARS Pharmaceuticals-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/7/2025Q1 2025SDGRSchrodinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A12.3512.35OCULOcular Therapeutix0.2610.2210.14SDGRSchrodingerN/A3.453.45SPRYARS Pharmaceuticals0.3011.0010.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%OCULOcular Therapeutix59.21%SDGRSchrodinger79.05%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipERASErasca14.40%OCULOcular Therapeutix2.30%SDGRSchrodinger8.60%SPRYARS Pharmaceuticals33.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.29 million242.49 millionOptionableOCULOcular Therapeutix230159.30 million155.64 millionOptionableSDGRSchrodinger79073.38 million67.07 millionOptionableSPRYARS Pharmaceuticals9098.21 million65.31 millionOptionableERAS, SPRY, SDGR, and OCUL HeadlinesRecent News About These CompaniesWhat Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'July 15 at 8:04 PM | sharewise.comSARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?July 15 at 1:01 PM | zacks.comWall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High?July 15 at 10:56 AM | zacks.comWhat Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'July 15 at 9:50 AM | zacks.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Consensus Price Target from BrokeragesJuly 14 at 2:57 AM | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Buy" by BrokeragesJuly 11, 2025 | marketbeat.comARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle EpinephrineJuly 10, 2025 | seekingalpha.comARS Pharmaceuticals: 'Betting On The Come'July 9, 2025 | seekingalpha.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 4.6% - Should You Buy?July 7, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Raises Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)July 6, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $254,850.00 in StockJuly 4, 2025 | insidertrades.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 15,000 Shares of StockJuly 3, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder James E. Flynn Sells 740,149 SharesJuly 2, 2025 | insidertrades.comJames E. Flynn Sells 740,149 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockJuly 1, 2025 | marketbeat.comPeregrine Capital Management LLC Boosts Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)July 1, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5% - Here's What HappenedJune 30, 2025 | marketbeat.comLisanti Capital Growth LLC Buys New Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)June 29, 2025 | marketbeat.com55,714 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Purchased by Matisse CapitalJune 28, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Upgraded at Wall Street ZenJune 28, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Sets New 12-Month High - Still a Buy?June 27, 2025 | marketbeat.comQ2 EPS Estimate for ARS Pharmaceuticals Boosted by AnalystJune 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeERAS, SPRY, SDGR, and OCUL Company DescriptionsErasca NASDAQ:ERAS$1.49 +0.05 (+3.47%) Closing price 04:00 PM EasternExtended Trading$1.48 -0.01 (-0.67%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Ocular Therapeutix NASDAQ:OCUL$11.38 +0.13 (+1.16%) Closing price 04:00 PM EasternExtended Trading$11.38 +0.00 (+0.04%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Schrodinger NASDAQ:SDGR$21.65 +0.40 (+1.88%) Closing price 04:00 PM EasternExtended Trading$21.86 +0.21 (+0.97%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.ARS Pharmaceuticals NASDAQ:SPRY$18.35 +0.48 (+2.69%) Closing price 04:00 PM EasternExtended Trading$18.13 -0.22 (-1.20%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
